Drug Type Personalized antigen vaccine |
Synonyms- |
Target |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 1 | US | - | 05 Jan 2022 |
Bladder Cancer | Phase 1 | US | 08 May 2019 | |
Locally Advanced Urothelial Carcinoma | Phase 1 | US | 08 May 2019 | |
Solid tumor | Phase 1 | US | - | 01 Apr 2016 |
Phase 1 | Transitional Cell Carcinoma Adjuvant | 9 | wyouozpotg(isujmmewnu) = grbzpmjikv xtlqybhzpw (paleyjgyrz ) | Positive | 05 Apr 2024 | ||
NCT02721043 (AACR2023) Manual | Phase 1 | 13 | huhemmdotw(dctxqlpzhc) = reached wzkqwmbpgd (lbfydzuyll ) Met View more | Positive | 14 Apr 2023 | ||
Phase 1 | Neoplasms Adjuvant | 15 | clkpbvmqii(toqorzxzut) = plbumowbin yiwgzijrnd (frrfnvmska ) View more | - | 01 Jul 2021 |